Ismail El-Hamamsy stood over the operating table at Mount Sinai in New York, not just repairing a heart but restoring a life expectancy—something once thought impossible for many adults with severe aortic valve disease. His team’s landmark study, following 455 adult patients who underwent the Ross Procedure between 2011 and 2019, has shattered long-standing assumptions about who can benefit from this intricate surgery. Once reserved primarily for younger patients without aortic regurgitation, the Ross Procedure is now proving its worth across a much broader spectrum of adults, including those over 50 and even up to age 67. The implications are profound: for the first time, aortic valve replacement isn’t just about survival—it’s about thriving with a lifespan that matches the general population.
The Ross Procedure replaces a diseased aortic valve with the patient’s own pulmonary valve, a living, adaptable tissue that functions like a natural aortic valve. Unlike mechanical or biological prostheses—neither of which can grow, repair, or fully replicate native hemodynamics—the Ross offers a dynamic solution. Mechanical valves demand lifelong anticoagulation, bringing risks of bleeding and dietary or lifestyle constraints. Biological valves degenerate over time, often requiring repeat surgeries, especially in younger or more active patients. But the Ross? It breathes, adapts, and endures.
At 12 years post-surgery, 96% of patients in the Mount Sinai cohort required no cardiac reintervention, and more than 98% showed no significant aortic valve dysfunction. Most strikingly, long-term survival matched that of the general population—rarely seen in any cardiac intervention. These results, published in the Journal of the American College of Cardiology, come from one of the largest and most rigorous North American studies on the procedure to date, all surgeries performed by a single high-volume team using a tailored surgical technique.
"The Ross procedure is the only aortic valve replacement operation that has consistently been shown to restore life expectancy to that of the general population matched for age and sex," says Dr. El-Hamamsy, the Randall B. Griepp, MD Professor of Cardiovascular Surgery at the Icahn School of Medicine. His words aren’t just hopeful—they’re backed by data. The study included patients with aortic regurgitation, once considered a risk factor for poorer outcomes, yet they too achieved excellent durability and function.
As cardiovascular medicine evolves, so does the vision of what’s possible. The Ross Procedure isn’t a relic of the past—it’s a growing standard of care for more adults than previously imagined. With continued refinement and wider access at centers of excellence, this living valve solution could redefine recovery for thousands. The heart, it turns out, can heal itself—when given the right tools.